833 abstracts found.



Results filter

Importance of the reference volume in assessing outlining performance for the purpose of training and revalidation

Year:

Session type:

Sarah Gwynne1,2, Emiliano Spezi2, Chris Hurt3, Stephen Falk4, Simon Gollins5, George Joseph2, John Staffurth2, Tom Crosby2
1Singleton Hospital, Swansea, UK, 2Velindre Cancer Centre, Cardiff, UK, 3Wales Cancer Trials Unit, Cardiff, UK, 4Bristol Haematology and Oncology Centre, Bristol, UK, 5North Wales Cancer Treatment Centre, Rhyl, UK

Liver stereotactic body radiation therapy (SBRT) for treatment refractory metastatic liver disease

Year:

Session type:

Katharine Aitken1, Irena Blasiak-Wal1, Maria Hawkins1
1Department of Radiotherapy, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK

Intensity Modulated Radiation Therapy (IMRT) with concurrent chemotherapy for Anal Cancer – Retrospective study evaluating toxicity profile and response rates

Year:

Session type:

Imran Petkar1, Young Lee1, Corrinne Brooks1, Diana Tait1, Maria Hawkins1
1Royal Marsden Hospital, Sutton, UK

A single centre randomised dosimetric study assessing the use of on-treatment cone beam CT (CBCT) scans for adaptive radiotherapy in patients with head and neck cancer (HNCa)

Year:

Session type:

Sindu Vivekanandan1, Daniel Emmens1, Ros Perry1, Christopher Scrase1
1Ipswich Hospital, Suffolk, UK

Is there a role for more than one test case in pre-trial outlining assessment?

Year:

Session type:

Sarah Gwynne1,2, Emiliano Spezi2, George Joseph2, Chris Hurt3, John Staffurth2, Tom Crosby2,4
1Singleton Hospital, Swansea, UK, 2Velindre Cancer Centre, Cardiff, UK, 3Wales Cancer Trials Unit, Cardiff, UK, 4Cardiff University, Cardiff, UK

Effect of public holidays causing interruptions and prolongation of radiotherapy in breast cancer patients

Year:

Session type:

Babita Jyoti1, Helen Wong1, Nicky Thorp1
1Clatterbridge Cancer Centre, Wirral, UK

Phase 0-I clinical trial of nelfinavir with hypofractionated radiotherapy for rectal cancer: Clinical safety and changes in tumour perfusion observed

Year:

Session type:

Esme Hill1,2, Jamie Franklin2, Monica Enescu3, Thinn Pwint2, Julia Schnabel3, Ewan Anderson2, Gina Brown4, W Gillies McKenna1, Tim Maughan1, Ricky Sharma1,2
1Gray Institute of Radiation Oncology and Biology, University of Oxford, Oxford, UK, 2The Churchill Hospital, Oxford, UK, 3Department of Engineering Science, University of Oxford, Oxford, UK, 4The Royal Marsden Hospital, Sutton, UK

Dose-escalated bladder radiotherapy: Result of first dose cohort

Year:

Session type:

Fiona McDonald1, Shaista Hafeez1,2, Susan Lallondrelle1, Victoria Harris1,2, Helen Taylor1, Karole Warren-Oseni1, Vibeke Hansen1, Kelly Jones1, Alan Thompson1, Vincent Khoo1, Robert Huddart1,2
1The Royal Marsden NHS Foundation Trust, Surrey, UK, 2The Institute of Cancer Research, Surrey, UK

Oxford Cancer Centre Ethics Forum

Year:

Session type:

Ketan Shah1, Michael Dunn2
1Oxford University Hospitals NHS Trust, Oxford, UK, 2The Ethox Centre, Oxford, UK

Routine data can estimate clinical outcomes in Head and Neck cancer: Results of a pilot study

Year:

Session type:

Matt Williams1,4, Zi Wei Liu2, Heather Fitzke3
1Dept. Clinical Oncology, University College Hospital, London, UK, 2Dept. Otolaryngology Head and Neck surgery, Colchester General Hospital, Colchester, UK, 3Dept. Imaging, University College Hospital, London, UK, 4Dept. Computer Science, University College London, London, UK

The DSB Biomarkers Pilot Study

Year:

Session type:

Ketan Shah1,2, Ketan A. Shah2, Katherine Vallis1,2
1University of Oxford, Oxford, UK, 2Oxford University Hospitals NHS Trust, Oxford, UK

Insufficiency fractures in patients radically treated with pelvic radiotherapy and chemotherapy for uterine and cervical cancer

Year:

Session type:

Qurrat Mehmood1, Marianne Beardwood2, Ric Swindell1, Lisa Barraclough1, Jacqueline Livsey1, Susan Davidson1
1The Christie NHS Foundation Trust, Manchester, UK, 2Royal Bolton Hospital, Bolton, UK

A simple method to refine prognosis in metastatic colorectal cancer

Year:

Session type:

Matt Williams1,2, Anna Lerner1, Ramsay Singer1
1Dept. Clinical Oncology, University College Hospital, London, UK, 2Dept. Computer Science, University College London, London, UK

The role of functional MRI to characterise tumour boost delineation in patients undergoing radical radiotherapy for muscle invasive bladder cancer (MIBC)

Year:

Session type:

Shaista Hafeez1,2, Mu Koh1, Aslam Sohaib1, Robert Huddart1,2
1The Royal Marsden Hospital, Sutton, UK, 2The Institue of Cancer Research, Sutton, UK

Cancer pain control

Year:

Session type:

Eduardo Bruera
The University of Texas MD Anderson Cancer Center, USA

Rituximab alone in the management of primary orbital lymphoma of the conjunctiva

Year:

Session type:

David Woolf1, Hariharan Kuhan1, Asad Qureshi1, Swee-Ling Wong1, Victoria Cohen1, Nick Plowman1
1St Bartholomew's Hospital, London, UK

Targeting the CRKL/Src Family Kinases in Rhabdomyosarcoma

Year:

Session type:

Lee Helman
National Cancer Institute, Bethesda, USA

Mammographic prediction of close or involved deep margin involvement following breast surgery

Year:

Session type:

David Hwang1,2, Lyndsae Wheen1,2, Russell Davies1,2
1Royal Devon and Exeter Hospital, Exeter, UK, 2University of Exeter, Exeter, UK

The breast screening review

Year:

Session type:

Harpal Kumar
Cancer Research UK, London, UK

Multi-disciplinary management for patients with oligometastases to the brain: results of a 5 year cohort study

Year:

Session type:

Jillian Maclean1, Naomi Fersht1, M Singhera1, Paul Mulholland1, Orla McKee1, Neil Kitchen1, Susan Short1
1University College London Hospitals NHS Foundation Trust, London, UK

The Breast Screening Review: evidence and recommendations

Year:

Session type:

Sir Michael Marmot
Institute of Health Equity, University College London, UK

Personalized Genomic Approaches and Pathway Identification for Individualized Prostate Cancer Therapy

Year:

Session type:

Robert Bristow
Ontario Cancer Institute/Princess Margaret Cancer Center & University of Toronto, Canada

Functional genomics, experimental models and cancer

Year:

Session type:

William Hahn
Dana-Farber Cancer Institute, Boston, USA

The use of sunitinib for pancreatic neuroendocrine tumours and metastatic paraganglioma in Weston Park Hospital, Sheffield

Year:

Session type:

Timothy Simmons1, Jonathan Wadsley1
1Weston Park Hospital, Sheffield, UK

Does an offline no-action-level correction protocol allow accurate delivery of radical radiotherapy in mid-lower oesophageal cancers?

Year:

Session type:

Qurrat Mehmood1, Julie Stratford1, Lubna Bhatt1, Alan Jackson1, Hamid Sheikh1
1The Christie NHS Foundation Trust, Manchester, UK

Therapeutic use of 131-Iodine meta-Iodobenzylguanidine in neuroendocrine tumours – the development and evaluation of a new radiopharmaceutical service

Year:

Session type:

Emma Bates1, Jonathan Wadsley1, Sally Walton1, C Taylor1
1Weston Park Hospital, Sheffield, UK

Cabazitaxel for patients with metastatic castration-resistant prostate cancer previously treated with a docetaxel-containing regimen: a single cancer centre experience using UK Early Access Programme and Cancer Drugs Fund

Year:

Session type:

Claire Kelly1, Stephanie Cornthwaite1, Alison Birtle1
1Rosemere Cancer Centre, Royal Preston Hospital, Preston, UK

Optimisation and Individualisation of Heart-Sparing Breast Radiotherapy Techniques (The HeartSpare Study)

Year:

Session type:

Frederick Bartlett1,2, Ruth Colgan1, Karen Carr1, Ellen Donovan1,2, Helen McNair1, Imogen Locke1, Anna Kirby1
1The Royal Marsden NHS Foundation Trust, Sutton, Surrey, UK, 2The Institute of Cancer Research, Sutton, Surrey, UK

Outcomes with surgery or radiotherapy following neoadjuvant chemotherapy for bladder cancer at the Edinburgh Cancer Centre

Year:

Session type:

Joanna Mackenzie1, Jahangeer Malik1, Gill Kerr1, Duncan McLaren1, Alastair Law1
1Edinburgh Cancer Centre, Edinburgh, UK

Feasibility of cone beam (CB) CT/ planning CT co-registration to estimate delivered doses in head and neck (HN) simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) treatments

Year:

Session type:

Andriana Michaelidou1, Rebecca Lynn1, David Convery1, Mary Lei1, Teresa Guerrero Urbano1
1Guys & St Thomas' NHS Foundation Trust, London, UK

Predictive factors for dose escalation with Cyberknife in oligometastatic disease

Year:

Session type:

Alison Tree1, Nicholas van As1, Karen Thomas1, Vincent Khoo1
1Royal Marsden NHS Foundation Trust, London, UK

Lung Stereotactic Ablative Radiotherapy (SABR) for Medically Inoperable Peripheral Stage I Non-small Lung Cancer (NSCLC) at the St. James’s Institute of Oncology (SJIO)

Year:

Session type:

Satiavani Ramasamy1, Himabindu Musunuru1, Vicky Sangha1, Michael Flatley1, Robert Turner1, Robert Stuart1, Katy Clarke1, Alan Needham2, John Lilley2, Michael Snee1, Kevin Franks1
1Department of Clinical Oncology, St James Institute of Oncology, Leeds, UK, 2Department of Medical Physics, St James Institute of Oncology, Leeds, UK

Introduction: Prostate Cancer – the androgen receptor takes centre stage

Year:

Session type:

Malcolm Mason
Cardiff University, UK

Clinical cancer genetics in the era of personalised cancer medicine

Year:

Session type:

Judy E. Garber
Dana-Farber Cancer Institute, Boston, USA

Androgen receptor co-regulatory proteins as alternative therapeutic targets in prostate cancer

Year:

Session type:

Craig Robson
Northern Institute for Cancer Research, University of Newcastle, UK

Biological insights arising from the identification of genes and pathways that are regulated by the androgen receptor

Year:

Session type:

Ian Mills
University of Oslo, Norway & Cancer Research UK Cambridge Institute, UK

Targeting the androgen receptor in castration-resistant prostate cancer

Year:

Session type:

Gerhardt Attard
The Institute of Cancer Research, London, UK

Introduction: Role of aspirin and other NSAIDs in cancer prevention

Year:

Session type:

Jack Cuzick
Wolfson Institute of Preventative Medicine, London, UK

Aspirin and cancer: Evidence from randomized trials

Year:

Session type:

Nancy Cook
Brigham and Women's Hospital & Harvard Medical School, Boston,USA

Aspirin and cancer risk: A meta-analysis to 2011

Year:

Session type:

Carlo La Vecchia
Istituto di Ricerche Farmacologiche Mario Negri & University of Milano, Milan, Italy

Promoting quality of life and care of advanced cancer patients: What factors matter most?

Year:

Session type:

Holly Prigerson
Dana-Farber Cancer Institute, Boston, USA

Cancer prevention with aspirin: Randomised trial evidence

Year:

Session type:

John Burn
Institute of Genetic Medicine and John Mathers (Institute of Ageing and Health), Newcastle University & D Tim Bishop (CRUK genetic Epidemiology, Leeds University) on behalf of the CAPP consortium, Newcastle, UK

Introduction: Clinical implications of clonal evolution and personalising therapy

Year:

Session type:

Faith Davies
The Institute of Cancer Research, London, UK

Introduction: Tumour angiogenesis

Year:

Session type:

Kairbaan Hodivala-Dilke
Barts Cancer Institute, London, UK

Risk-driven therapy in acute myeloid leukaemia

Year:

Session type:

Alan Burnett
Cardiff University, UK

Histidine-rich glycoprotein in tumour vessel normalization and anti-tumour immune responsiveness

Year:

Session type:

Lena Claesson-Welsh
Uppsala University, Sweden

Founding clones and evolving subclones: Insights in acute myeloid leukaemia from next-generation sequencing

Year:

Session type:

John Welch
Washington University, St Louis, USA

Time to branch? Endothelial cell dynamics regulating vascular patterning

Year:

Session type:

Holger Gerhardt
Cancer Research UK London Research Institute, UK

The clinical impact of advances in the genetic understanding of cancer

Year:

Session type:

Gareth Morgan
The Institute of Cancer Research, London, UK

Tumour invasion and metastasis: Reduction by concurrent inhibition of c-MET and VEGF signalling

Year:

Session type:

Donald M. McDonald
University of California, San Francisco, USA